These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25145366)

  • 1. Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1).
    Kerr A; Exeter D; Hanham G; Grey C; Zhao J; Riddell T; Lee M; Jackson R; Wells S
    N Z Med J; 2014 Aug; 127(1400):39-69. PubMed ID: 25145366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and use of mapping techniques to describe the geographical distribution of medication dispensing for the secondary prevention of atherosclerotic CVD in New Zealand: VIEW-2.
    Exeter DJ; Zhao J; Hanham G; Grey C; Wells S; Kerr A
    N Z Med J; 2014 Aug; 127(1400):70-80. PubMed ID: 25145367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stakeholder engagement for the New Zealand Atlas of Healthcare Variation: cardiovascular disease secondary prevention: VIEW-3.
    Grey C; Wells S; Exeter DJ; Hanham G; Zhao J; Kerr AJ
    N Z Med J; 2014 Aug; 127(1400):81-91. PubMed ID: 25145368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
    Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
    Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15).
    Mehta S; Wells S; Riddell T; Kerr A; Pylypchuk R; Marshall R; Ameratunga S; Chan WC; Thornley S; Crengle S; Harrison J; Drury P; Elley CR; Bell F; Jackson R
    J Prim Health Care; 2011 Jun; 3(2):93-101. PubMed ID: 21625656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are at-risk New Zealand women receiving recommended cardiovascular preventive therapy?
    Bupha-Intr O; Rose SB; Lawton BA; Elley CR; Dowell AC
    N Z Med J; 2010 Feb; 123(1309):26-36. PubMed ID: 20186240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare.
    Hyun KK; Redfern J; Patel A; Peiris D; Brieger D; Sullivan D; Harris M; Usherwood T; MacMahon S; Lyford M; Woodward M
    Heart; 2017 Apr; 103(7):492-498. PubMed ID: 28249996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin adherence is lower in primary than secondary prevention: A national follow-up study of new users.
    Sigglekow F; Horsburgh S; Parkin L
    PLoS One; 2020; 15(11):e0242424. PubMed ID: 33211724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.
    Lafeber M; Grobbee DE; Spiering W; van der Graaf Y; Bots ML; Visseren FL;
    Eur J Prev Cardiol; 2013 Oct; 20(5):771-8. PubMed ID: 22649123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
    BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four out of ten patients are not taking statins regularly during the 12 months after an acute coronary event.
    Thornley S; Marshall R; Chan WC; Kerr A; Harrison J; Jackson G; Crengle S; Wright C; Wells S; Jackson R
    Eur J Prev Cardiol; 2012 Jun; 19(3):349-57. PubMed ID: 21450568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of removing funding restrictions for atorvastatin differed across sociodemographic groups among New Zealanders hospitalised with cardiovascular disease: a national data linkage study.
    Mehta S; Wells S; Jackson R; Harrison J; Kerr A
    N Z Med J; 2016 Oct; 129(1443):18-29. PubMed ID: 27736849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Length of initial prescription at hospital discharge and long-term medication adherence for elderly patients with coronary artery disease: a population-level study.
    Ivers NM; Schwalm JD; Jackevicius CA; Guo H; Tu JV; Natarajan M
    Can J Cardiol; 2013 Nov; 29(11):1408-14. PubMed ID: 23816280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dispensing data captures individual-level use of aspirin for cardiovascular disease prevention, despite availability over-the-counter.
    Selak V; Gu Y; Rafter N; Crengle S; Kerr AJ; Bullen C
    N Z Med J; 2016 May; 129(1435):21-8. PubMed ID: 27355165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Socioeconomic Factors, Secondary Prevention Medication, and Long-Term Survival After Coronary Artery Bypass Grafting: A Population-Based Cohort Study From the SWEDEHEART Registry.
    Nielsen SJ; Karlsson M; Björklund E; Martinsson A; Hansson EC; Malm CJ; Pivodic A; Jeppsson A
    J Am Heart Assoc; 2020 Mar; 9(5):e015491. PubMed ID: 32114890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Equity in statin use in New Zealand.
    Norris P; Horsburgh S; Becket G; Keown S; Arroll B; Lovelock K; Crampton P; Cumming J; Herbison P
    J Prim Health Care; 2014 Mar; 6(1):17-22. PubMed ID: 24624407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An observational study of how clinicians use cardiovascular risk assessment to inform statin prescribing decisions.
    Robinson T; Jackson R; Wells S; Kerr A; Marshall R
    N Z Med J; 2017 Oct; 130(1463):28-38. PubMed ID: 28981492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of alternative cardiovascular risk prediction equations for population health planning: a routine health data linkage study of 1.7 million New Zealanders.
    Mehta S; Jackson R; Pylypchuk R; Poppe K; Wells S; Kerr AJ
    Int J Epidemiol; 2018 Oct; 47(5):1571-1584. PubMed ID: 30010781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.